» Articles » PMID: 29499103

Precision Medicine in Diabetes Prevention, Classification and Management

Overview
Specialty Endocrinology
Date 2018 Mar 3
PMID 29499103
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Diabetes has become a major burden of healthcare expenditure. Diabetes management following a uniform treatment algorithm is often associated with progressive treatment failure and development of diabetic complications. Recent advances in our understanding of the genomic architecture of diabetes and its complications have provided the framework for development of precision medicine to personalize diabetes prevention and management. In the present review, we summarized recent advances in the understanding of the genetic basis of diabetes and its complications. From a clinician's perspective, we attempted to provide a balanced perspective on the utility of genomic medicine in the field of diabetes. Using genetic information to guide management of monogenic forms of diabetes represents the best-known examples of genomic medicine for diabetes. Although major strides have been made in genetic research for diabetes, its complications and pharmacogenetics, ongoing efforts are required to translate these findings into practice by incorporating genetic information into a risk prediction model for prioritization of treatment strategies, as well as using multi-omic analyses to discover novel drug targets with companion diagnostics. Further research is also required to ensure the appropriate use of this information to empower individuals and healthcare professionals to make personalized decisions for achieving the optimal outcome.

Citing Articles

Development and validation of a prognostic model for critically ill type 2 diabetes patients in ICU based on composite inflammatory indicators.

Liu L, Zhao Y, Cheng Z, Li Y, Liu Y Sci Rep. 2025; 15(1):3627.

PMID: 39880877 PMC: 11779909. DOI: 10.1038/s41598-025-87731-z.


Exploring the Role of Health-care Professionals and Impact of Precision Medicine on Health Outcomes and Efficiency.

Shrivastava S, Marar A, Bobhate P, Badge A Contemp Clin Dent. 2025; 15(4):295-297.

PMID: 39845622 PMC: 11749050. DOI: 10.4103/ccd.ccd_323_24.


Development of a Secure Web-Based Medical Imaging Analysis Platform: The AWESOMME Project.

Diot-Dejonghe T, Leporq B, Bouhamama A, Ratiney H, Pilleul F, Beuf O J Imaging Inform Med. 2024; 37(5):2612-2626.

PMID: 38689149 PMC: 11522235. DOI: 10.1007/s10278-024-01110-0.


Methods for Integrating Trials and Non-experimental Data to Examine Treatment Effect Heterogeneity.

Brantner C, Chang T, Nguyen T, Hong H, Stefano L, Stuart E Stat Sci. 2024; 38(4):640-654.

PMID: 38638306 PMC: 11025720. DOI: 10.1214/23-sts890.


Novel Therapies in Diabetes: A Comprehensive Narrative Review of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Beyond.

Olanrewaju O, Sheeba F, Kumar A, Ahmad S, Blank N, Kumari R Cureus. 2024; 15(12):e51151.

PMID: 38283440 PMC: 10811430. DOI: 10.7759/cureus.51151.


References
1.
Hou W, Zhang D, Lu W, Zheng T, Wan L, Li Q . Polymorphism of organic cation transporter 2 improves glucose-lowering effect of metformin via influencing its pharmacokinetics in Chinese type 2 diabetic patients. Mol Diagn Ther. 2015; 19(1):25-33. DOI: 10.1007/s40291-014-0126-z. View

2.
Hamming K, Soliman D, Matemisz L, Niazi O, Lang Y, Gloyn A . Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K(+) channel. Diabetes. 2009; 58(10):2419-24. PMC: 2750221. DOI: 10.2337/db09-0143. View

3.
Kang E, Park S, Kim H, Kim C, Ahn C, Cha B . Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetes. Clin Pharmacol Ther. 2005; 78(2):202-8. DOI: 10.1016/j.clpt.2005.04.013. View

4.
Cauchi S, Meyre D, Durand E, Proenca C, Marre M, Hadjadj S . Post genome-wide association studies of novel genes associated with type 2 diabetes show gene-gene interaction and high predictive value. PLoS One. 2008; 3(5):e2031. PMC: 2346547. DOI: 10.1371/journal.pone.0002031. View

5.
Katra B, Klupa T, Skupien J, Szopa M, Nowak N, Borowiec M . Dipeptidyl peptidase-IV inhibitors are efficient adjunct therapy in HNF1A maturity-onset diabetes of the young patients--report of two cases. Diabetes Technol Ther. 2010; 12(4):313-6. DOI: 10.1089/dia.2009.0159. View